T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
|Podcasts|April 10, 2019
Highlighting Breakthroughs in Breast Cancer in Nashville
Author(s)Onclive Team
We traveled to Nashville, Tennessee, for a State of the Science Summit™ on Breast Cancer, which focused on some of the practice-changing updates that have been occurring in the field.
Advertisement
We recently ventured to Nashville, Tennessee for a State of the Science Summit™ on Breast Cancer. At this conference, we sat down with faculty from Sarah Cannon Research Institute, HCA Midwest Health, Virginia Cancer Specialists, and Memorial Sloan Kettering Cancer Center to discuss some of the practice-changing updates that have been occurring in the field.
Advertisement
Related to this article
Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.
A surgical team from Huntsman Cancer Institute at the University of Utah has performed the first robotic mastectomy in the Mountain West.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Read a refresh of breast cancer FDA news from July, including the first approval of a pan-PI3K/mTOR inhibitor combination and a pegfilgrastim biosimilar.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5